Big Pharma, UK Universities Launch 'Unique' Early Drug Development Fund
This article was originally published in Scrip
Executive Summary
AstraZeneca plc, GlaxoSmithKline plc and Johnson & Johnson are investing £30m between them into a new fund aimed at advancing academic therapeutic research from three leading universities.
You may also be interested in...
Family Offices Boost Life Sciences Partners’s Over-Subscribed Fifth Fund
Family offices are increasing their exposure to Europe’s life sciences sector by investing in venture capital funds, including the just-closed over-subscribed fifth fund from Life Sciences Partners.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.